Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?

Mayo Clinic Proceedings
Michael J Mauro, Richard T Maziarz

Abstract

Hematopoietic stem cell transplantation has been a cornerstone of therapy for chronic myelogenous leukemia (CML) for more than 15 years and is still a standard treatment option for patients with CML. The advent of imatinib mesylate, an inhibitor of the molecular defect driving CML, the BCR-ABL tyrosine kinase, has rewritten treatment algorithms for this disease and has shifted focus away from allografting. Despite advances in stem cell transplantation, such as broader availability with the use of modified conditioning regimens, use of allografting has diminished. Also, the nearly universal patient exposure to imatinib or other kinase inhibitors before transplantation may affect the biology of the disease that is currently being treated with an allograft and ultimately may affect outcomes. Exceedingly high rates of meaningful and stable response with longer follow-up continue to drive enthusiasm for imatinib use, and understanding of resistance mechanisms has driven rapid investigation of second-generation tyrosine kinase inhibitors to address imatinib failure and suboptimal response. In most patients, imatinib reduces CML to a minimal residual disease state in which options to further deepen remission, such as immunotherapy, ar...Continue Reading

References

Apr 2, 1998·The New England Journal of Medicine·J A HansenC Anasetti
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Mar 15, 2003·The New England Journal of Medicine·Karl Peggs, Stephen Mackinnon
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth A HahnUNKNOWN IRIS Investigators
Jun 5, 2003·Seminars in Hematology·Tim Hughes, Susan Branford
Aug 28, 2003·Bone Marrow Transplantation·Richard T Maziarz, Michael J Mauro
Oct 10, 2003·The New England Journal of Medicine·Tim P HughesUNKNOWN International Randomised Study of Interferon versus STI571 (IRIS) Study Group
Jan 17, 2004·Experimental Hematology·John M Goldman
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bin PengRenaud Capdeville
Sep 21, 2004·Blood·Jorge CortesHagop Kantarjian
Feb 1, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Vivian G OehlerWilliam Bensinger

❮ Previous
Next ❯

Citations

Mar 21, 2009·International Urology and Nephrology·Mark A Marinella
Jul 25, 2014·Leukemia & Lymphoma·Gemma Osca-GelisRafael Marcos-Gragera
Feb 9, 2007·Mayo Clinic Proceedings·Alex A AdjeiAyalew Tefferi
Oct 3, 2008·Mayo Clinic Proceedings·S Vincent Rajkumar
Aug 15, 2006·Blood Cells, Molecules & Diseases·William SimonMarshall A Lichtman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.